English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn INRS team is investigating the relationship between body mass and the risk of developing cancer
Tag: prostate cancer
Protein in prostate cancer may inhibit tumor growth
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Protein in prostate cancer may inhibit tumor growth
Researchers identified the protein responsible for cancer’s aggressiveness
Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month
New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…
Oncotarget: The drug sensitivity of hepatocellular cancer cells
‘Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months’
Mount Sinai identifies the causes of racial disparity in prostate cancer in a multi-institutional study
MEDIA ADVISORY Senior Author: Ash Tewari, MBBS, MCh, Professor and System Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Prostate Cancer…
Study finds lower mortality rate for men at high risk for death from prostate cancer who received early postoperative radiation therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
AI outperforms humans in creating cancer treatments, but do doctors trust it? It depends!
The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.
Oncotarget: E6-specific inhibitors as therapeutics for HPV+ head and neck carcinomas
‘Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence’
Oncotarget: Lung squamous cell carcinoma tumors reveal therapeutic alterations
Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually’
When should screening start for men with a family history of prostate cancer?
Some men reach the risk threshold to start screening up to 11 years sooner than guidelines recommend
SWOG researchers advance cancer care at virtual ASCO 2021
“SWOG always brings an impressive portfolio of work to the ASCO annual meeting,” said SWOG Chair Charles D. Blanke, MD, “and this year I’m particularly excited about the research our investigators are presenting because it includes results that are likely…
Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer
CLEVELAND: According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.
The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer. The H6PD levels also were elevated in biopsied patient tumors, suggesting the protein might be targeted in patients for treatment.
Cleveland’s University Hospitals Urology Institute offers alternative prostate cancer biopsy technique
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
UVA develops new tools to battle cancer, advance genomics research
University of Virginia School of Medicine scientists have developed important new resources that will aid the battle against cancer and advance cutting-edge genomics research. UVA’s Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to…
Cleveland clinic researchers identify new drug target for treating aggressive prostate cancer
Findings published in Science Translational Medicine
Racemases: The hunt for drugs to neutralise these critical enzymes
Scientists from the University of Bath in the UK explore racemases and propose strategies for finding drugs that target these important enzymes.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
Impact Journals to present on scientific integrity at SSP Annual Meeting
Impact Journals is an exhibitor/sponsor and will be presenting our scientific integrity process at the Society for Scholarly Publishing (SSP) Annual Meeting, occurring virtually from May 24-27, 2021
Researchers use environmental data to assess prostate cancer diagnosis factors
Environmental quality is associated with advanced-stage prostate cancer at diagnosis, according to a new study by University of Illinois Chicago researchers. Prostate cancer is up to 57% heritable, with the remainder attributed to environmental exposures. However, studies on those environmental factors and prostate cancer aggressiveness…
New insights into androgen’s action could boost battle against prostate cancer
Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells – and the discovery could boost efforts to develop better treatments for prostate, ovarian and breast cancers. The findings shed…
Frontiers in Clinical Drug Research – Anti-Cancer Agents
Bentham Science has recently launched the new volume of the book, Frontiers in Clinical Drug Research – Anti-Cancer Agents. Frontiers in Clinical Drug Research – Anti-Cancer Agents is a book series essential for pharmaceutical scientists, postgraduate students and researchers seeking…
City of Hope opens Phase 2 trial to test if mushroom tablets could slow prostate cancer
Scientists investigate if City of Hope’s natural supplement derived from white button mushroom could lower prostate-specific antigen levels, an indicator of prostate cancer
Male bladder cancer vulnerability could lead to a new treatment approach
UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors – a type of protein specific to men – may destroy cancer cells. Focusing on this male protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men.
12 open arms in NCI-MATCH treatment trial await patients with advanced or rare cancers
A new study arm opens, expanding patients’ potential to qualify for the trial when they may not have other options; the available treatments target tumor defects with drugs that show efficacy evidence; testing labs continue to identify trial candidates
First clinical trials set for MRI cancer detection
Case Western Reserve University-developed imaging agent for MRI prostate cancer detection gets FDA approval for safety trials, set to begin in May in Columbus
New Urine-based Test Holds Promise for Detecting Aggressive Prostate Cancer
A new, urine-based test for aggressive prostate cancer being developed at the University of Michigan uses next-generation sequencing to assess 15 biomarkers to find cancer that can be missed by biopsies or imaging tests.
Novel drug regenerates erectile nerves damaged by prostate surgery
April 19, 2021–(BRONX, NY) –Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was…
Bone microenvironment fosters breast cancer metastatic behavior
Two studies led by Baylor College of Medicine shed new light on the unanswered question of why estrogen receptor-positive (ER+) breast cancer sometimes grows back in the bone and spreads to other tissues despite effective endocrine therapies directed at ER.…
Study: New Approach May Boost Prostate Cancer Immunotherapies
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Study: New approach may boost prostate cancer immunotherapies
Strategy focuses on reprogramming tissues surrounding the tumor to help the body’s immune system attack the cancer
Researchers Awarded Funding to Lead National Discussion on Active Surveillance for Men with Low-Risk Prostate Cancer
Researchers at the University of Maryland School of Medicine (UMSOM) have been awarded $100,000 in funding through the Eugene Washington PCORI Engagement Awards, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The funds will support a national discussion and conference aimed at identifying evidence gaps to guide future research on the use of active surveillance to monitor low-risk prostate cancers. This serves as an alternative to immediate treatment with surgery, radiation or hormone therapy which all have potential debilitating side effects.
John D. Carpten elected fellow of AACR Academy
American Association for Cancer Research honors distinguished USC Norris Comprehensive Cancer Center scientist
CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
Bottom Line: Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). Journal in Which the Study was Published: Molecular Cancer Research , a…
Oncotarget: Phase 1 study of Z-Endoxifen in patients with solid tumors
The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy.
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology . The chronic complications, which occurred in 43% of patients, affected the joints…
NCCN 2021 Virtual Annual Conference addresses cancer care in a year of crisis and innovation
Live virtual conference drew global oncology professionals to share best practices and highlight advances and issues in cancer care
Drug used during pregnancy may increase cancer risk in mother’s adult children
Exposure in the womb to a drug used to prevent miscarriage appears to raise the offspring’s cancer risk decades later, especially for colorectal and prostate cancers, researchers have found. They will present the results of their new study Tuesday at ENDO 2021, the Endocrine Society’s annual meeting.
Increasing diversity in clinical trials the focus of new stand up to cancer team
The Health Equity Breakthrough Team includes clinical cancer specialists and experts in the social science components of community health
Drug used during pregnancy may increase cancer risk in mother’s adult children
Hydroxyprogesterone caproate may contribute to increasing rates of early-onset cancer, researchers say
Having a single personal doctor may sometimes lead to unnecessary tests
Patient care by a single primary care physician is associated with many health benefits, including increased treatment adherence and decreased hospital admissions and mortality risk. But can the relationship built between doctor and patient also lead to unnecessary care? A…
Prostate cancer uses metabolic switch to thrive after hormone therapy
Finding points toward a new approach that directly targets the cancer’s fuel source
Study could help develop biosensors for non-invasive diagnosis of diseases
Brazilian researchers tested the capacity of different materials to produce sensors for the detection of PCA3, a gene that is overexpressed in prostate cancer. The technique can also be used to diagnose infectious diseases, including COVID-19.
Oncotarget: Hispanic Chronic myelomonocytic leukemia patients
This Oncotarget study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1
Oncotarget: Ibuprofen disrupts protein complex in colorectal cells
The Oncotarget data shed new light on the biochemical mechanisms behind ibuprofen’s action on alternative spliced RAC1B and may support its use in personalized approaches to CRC therapy or chemoprevention regimens.
Oncotarget: Predictors of immunotherapy benefit in Merkel cell carcinoma
Dr. Glenn J. Hanna from CCR/NCI in Bethesda, MD as well as The Dana-Farber Cancer Institute in Boston Massachusetts said, “Merkel cell carcinoma (MCC) is a relatively rare cancer, with roughly 400 cases per 100,000 persons each year in the United States”
White button mushrooms could slow progression of prostate cancer
The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
White button mushrooms could slow progression of prostate cancer
Mouse study suggests mushrooms may suppress androgen receptor activity
LSU Veterinary School receives $11M COBRE grant for a pre-clinical cancer research center
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11 million grant to establish a Center of Biomedical Research Excellence, or COBRE. The COBRE funds will create the Center for Pre-Clinical Cancer Research, or Cancer…